Korean J Med.  2004 Sep;67(3):274-281.

5-Fluorouracil, heptaplatin and UFT combination chemotherapy for advanced or recurrent gastric cancer

• Kwon JH
• Park EK
• Lee JH
• Lee SJ

Abstract

BACKGROUND: This study was performed in patients with advanced or recurrent gastric cancer to evaluate the efficacy and feasibility of combination chemotherapy with 5-fluorouracil, heptaplatin, and UFT.
METHODS
Total 20 patients with advanced or recurrent gastric cancer were enrolled from April 1, 2000 to December 31, 2001 and analyzed for response, toxicity, and survival. The regimen consisted of heptaplatin 400 mg/m2 (day 1), 5-flurouracil 1,000 mg/m2/day (day 1 to 5, continuous infusion) and 5-FU 225 mg/m2/day (day 6 to 12, continuous infusion) or UFT 400 mg/d (day 6 to 22). The treatment was repeated by 28 days.
RESULTS
17 patients could be evaluated. The overall response rate was 47.1% (2 complete responses and 6 partial responses), and the median duration of response was 6.2 months (95% CI: range, 1.0~12.4 months). Median survival of the 20 patients was 11.7 months (95% CI: range, 4.2~19.8 months). Grade 4 hematologic toxicity with sepsis occurred in 1 cycle.
CONCLUSION
Based on these results, this combination chemotherapy seems to be useful for advanced or recurrent gastric cancer.

Keyword

Gastric cancer; Heptaplatin; Fluorouracil

MeSH Terms

Drug Therapy, Combination*
Fluorouracil*
Humans
Sepsis
Stomach Neoplasms*
Fluorouracil